+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Intranasal Drug Delivery - Global Strategic Business Report

  • PDF Icon

    Report

  • 459 Pages
  • March 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 516888
The global market for Intranasal Drug Delivery is estimated at US$59.1 Billion in 2023 and is projected to reach US$92.6 Billion by 2030, growing at a CAGR of 5.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Liquid Delivery Devices segment, which is expected to reach US$38 Billion by 2030 with a CAGR of 5.4%. The Powder Delivery Devices segment is also set to grow at 6.5% CAGR over the next 8 years.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $24.6 Billion in 2023, and China, forecasted to grow at an impressive 7.8% CAGR to reach $8.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Intranasal Drug Delivery Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Intranasal Drug Delivery Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Intranasal Drug Delivery Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Acorda Therapeutics, Inc., Ferring Pharmaceuticals Inc, Bespak Europe Ltd., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 77 Featured):

  • Acorda Therapeutics, Inc.
  • Ferring Pharmaceuticals Inc
  • Bespak Europe Ltd.
  • Breckenridge Pharmaceutical, Inc.
  • Janssen Global Services LLC
  • Hikma Pharmaceuticals PLC
  • Biologische Heilmittel Heel GmbH
  • Evoke Pharma, Inc.
  • KemPharm, Inc.
  • Impel NeuroPharma
  • Actiza Pharmaceutical Pvt., Ltd.
  • Covis Pharma
  • H&T Presspart Manufacturing Ltd.
  • Biomedica International
  • Alchemy Pharmatech Ltd.

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Intranasal Drug Delivery - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Intranasal Drug Delivery: A Prelude
  • Leading Indications and APIs Amenable to Nasal Drug Delivery
  • Regional Market Analysis
  • Why Nasal Application is Garnering NoTable Attention for Drug Delivery
  • Limitations of Intranasal Drug Delivery
  • Overview of the Traditional Drug Administration Routes, Molecular Weight Capabilities, and Dosage Range
  • Drug Delivery Pathways Related to the Nasal Cavity
  • Systemic delivery and Local Delivery Routes
  • Differences between Systemic Delivery and Local Effects
  • Challenges Involved In Formulating Nasal Drugs
  • Intranasal Cavity: An Attractive Drug Delivery Route to Cross the Blood Brain Barrier
  • Nose-to-Brain Drug Delivery: An Evolving Area of Interest
  • Factors Inhibiting Nose-to-Brain Transportation of Drugs
  • Bioavailability: An Important Facet of Intranasal Drug Delivery
  • Traditional Vs. Advanced Intranasal Drug Formulation Types
  • Type of Nasal Delivery Vehicles with Select Therapeutic Agents and Area of Application
  • Select FDA-Approved Nasal Products Compound (Trade Name) Indication Dosage Form Year
  • Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rise in Prevalence of COPD Drives Opportunities
  • Global Prevalence of COPD: Percentage of Men and Women Affected by Age Group
  • Pharmaceutical and Medical Device Companies Vie to Develop New Intranasal Therapeutics for Allergic Rhinitis Patients
  • Prevalence Percentage of COPD, Asthma, and Allergic Rhinitis for Select Countries
  • The US - FDA Approved Intranasal Corticosteroids (INAC) and Intranasal Antihistamines (INAH) for Treating Allergic Rhinitis
  • The US - FDA Approved Nasal Spray Medication Types (excluding INAC & INAH) for Allergic Rhinitis Treatment
  • Intranasal Corticosteroids : A Potential Treatment for Debilitating Chronic Rhinosinusitis Disease
  • Select Intranasal Corticosteroid Brands for Adult and Pediatric Usage
  • Manufacturers Focus on Improved Nasal Delivery Platforms
  • Controlled Release Technology is the Buzz Word
  • Research on Nanocarrier-Based Intranasal Drug Delivery Systems Picks Up Pace
  • Potential Role in Treatment and Management of Coronavirus Infection
  • Self-Administration of Drugs Brings Intranasal Drug Delivery into the Spotlight
  • Nasal Drug Delivery Offers New Opportunities for Drug Developers as Patent Cliffs Usher in Dusk of Blockbuster Era
  • Active Pharmaceutical Ingredients Used in Formulations for Nasal Drug Delivery with Related Indications
  • Increasing R&D Unlocks New Therapeutic Areas for Nasal Drug Delivery
  • Intranasal Therapeutics Delivery: A High Potential Method for Treating CNS Diseases
  • Researchers Develop Nasal Spray Treatment for Parkinson’s Disease
  • Future Opportunities in CNS Space
  • Intranasal Delivery of Stem Cells: A Primary Strategy for Treatment of CNS Disorders
  • Intranasal Delivery of Stem Cells: Limitations
  • Diagnosed Prevalence Cases of Parkinson’s Disease Across Select Countries
  • Intranasal Delivery of Peptide-Based Pharmaceuticals
  • Select Protein, Peptide & Non-Peptide Drugs Available as Nasal Spray Solutions in the Marketplace
  • Select List of Nasal Biologics Available in the Market
  • Benefits of Bi-Directional Nasal Drug Delivery
  • Rise in Interest in Preservative-free Nasal Spray Formulations
  • Burgeoning Geriatric Populace Spurs Growing Demand for Intranasal Drug Therapies
  • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Appendix: List of Select Intranasal Drugs in Phase III Clinical Trials
  • List of Select Intranasal Drugs for Pain Management in Phase III Clinical Trials
  • Select Intranasal Drugs for Cancer in Phase III Clinical Trials
  • Select Intranasal Drugs for Diabetes in Phase III Clinical Trials
  • Select Intranasal Drugs for Nasal Polyps in Phase III Clinical Trials
  • Select Intranasal Drugs for Depression in Phase III Clinical Trials
  • Select Intranasal Drugs for Chronic Sinusitis in Phase III Clinical Trials
  • Select Intranasal Drugs for Migraine in Phase III Clinical Trials
  • Intranasal Drugs for Allergic Rhinitis in Phase III Clinical Trials
  • Select Intranasal Drugs for Diabetes Mellitus in Phase III Clinical Trials
  • Select Intranasal Drugs for Covid-19 in Phase III Clinical Trials
  • Select Intranasal Drugs for Covid-19 in Phase III Clinical Trials
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Liquid Delivery Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 2: World Historic Review for Liquid Delivery Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2016 through 2022 and % CAGR
  • Table 3: World 14-Year Perspective for Liquid Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2024 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Powder Delivery Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 5: World Historic Review for Powder Delivery Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2016 through 2022 and % CAGR
  • Table 6: World 14-Year Perspective for Powder Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2024 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Pressurized Metered Dose Inhalers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 8: World Historic Review for Pressurized Metered Dose Inhalers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2016 through 2022 and % CAGR
  • Table 9: World 14-Year Perspective for Pressurized Metered Dose Inhalers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2024 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 11: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2016 through 2022 and % CAGR
  • Table 12: World 14-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2024 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Respiratory Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 14: World Historic Review for Respiratory Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2016 through 2022 and % CAGR
  • Table 15: World 14-Year Perspective for Respiratory Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2024 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 17: World Historic Review for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2016 through 2022 and % CAGR
  • Table 18: World 14-Year Perspective for Neurological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2024 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Pain Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 20: World Historic Review for Pain Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2016 through 2022 and % CAGR
  • Table 21: World 14-Year Perspective for Pain Management by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2024 & 2030
  • Table 22: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2016 through 2022 and % CAGR
  • Table 24: World 14-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2024 & 2030
  • Table 25: World Intranasal Drug Delivery Market Analysis of Annual Sales in US$ Million for Years 2016 through 2030
  • Table 26: World Recent Past, Current & Future Analysis for Intranasal Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 27: World Historic Review for Intranasal Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2016 through 2022 and % CAGR
  • Table 28: World 14-Year Perspective for Intranasal Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2016, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
CANADA
JAPAN
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
CHINA
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
EUROPE
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
FRANCE
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
GERMANY
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
ITALY
UNITED KINGDOM
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
AUSTRALIA
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Acorda Therapeutics, Inc.
  • Ferring Pharmaceuticals Inc
  • Bespak Europe Ltd.
  • Breckenridge Pharmaceutical, Inc.
  • Janssen Global Services LLC
  • Hikma Pharmaceuticals PLC
  • Biologische Heilmittel Heel GmbH
  • Evoke Pharma, Inc.
  • KemPharm, Inc.
  • Impel NeuroPharma
  • Actiza Pharmaceutical Pvt., Ltd.
  • Covis Pharma
  • H&T Presspart Manufacturing Ltd.
  • Biomedica International
  • Alchemy Pharmatech Ltd.

Table Information